TrialScientific reports2023

Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients.

Hyung Woo Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.